Back to Search
Start Over
Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells.
- Source :
-
Translational lung cancer research [Transl Lung Cancer Res] 2024 Mar 29; Vol. 13 (3), pp. 678-683. Date of Electronic Publication: 2024 Mar 18. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-793/coif). C.M.H. and R.M. are employees of Leucid Bio Ltd. J.M. is the founder, Chief Scientific Officer and shareholder of Leucid Bio Ltd. The authors have no other conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 2218-6751
- Volume :
- 13
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Translational lung cancer research
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38601439
- Full Text :
- https://doi.org/10.21037/tlcr-23-793